GT Biopharma, Inc. (GTBP)
USD 2.05
(-21.46%)
USD 2.05
(-21.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.59 Million USD | 62.95% |
| 2022 | -20.5 Million USD | 65.07% |
| 2021 | -58.69 Million USD | -85.64% |
| 2020 | -31.61 Million USD | 22.46% |
| 2019 | -40.77 Million USD | 84.27% |
| 2018 | -259.18 Million USD | -80.94% |
| 2017 | -143.24 Million USD | -781.06% |
| 2016 | 21.03 Million USD | 164.27% |
| 2015 | -32.72 Million USD | -39.32% |
| 2014 | -23.48 Million USD | -4588.42% |
| 2013 | -501 Thousand USD | 90.31% |
| 2012 | -5.17 Million USD | -39.76% |
| 2011 | -3.7 Million USD | -23.54% |
| 2010 | -2.99 Million USD | -33.35% |
| 2009 | -2.24 Million USD | 55.13% |
| 2008 | -5 Million USD | -1162.85% |
| 2007 | 471 Thousand USD | 109.53% |
| 2006 | -4.94 Million USD | -58.89% |
| 2005 | -3.1 Million USD | -17.06% |
| 2004 | -2.65 Million USD | -235.78% |
| 2003 | -791 Thousand USD | 3.77% |
| 2002 | -822 Thousand USD | 76.48% |
| 2001 | -3.49 Million USD | 25.38% |
| 2000 | -4.68 Million USD | -4.2% |
| 1999 | -4.49 Million USD | 36.69% |
| 1998 | -7.1 Million USD | -36.54% |
| 1997 | -5.2 Million USD | 13.33% |
| 1996 | -6 Million USD | 32.58% |
| 1995 | -8.9 Million USD | -58.93% |
| 1994 | -5.6 Million USD | -273.33% |
| 1993 | -1.5 Million USD | -400.0% |
| 1992 | -300 Thousand USD | -50.0% |
| 1991 | -200 Thousand USD | -122.22% |
| 1990 | 900 Thousand USD | 28.57% |
| 1989 | 700 Thousand USD | 600.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.71 Million USD | -63.72% |
| 2024 Q1 | -2.26 Million USD | 23.5% |
| 2023 Q4 | -2.96 Million USD | -22.6% |
| 2023 Q2 | -1.99 Million USD | 49.01% |
| 2023 Q1 | -3.9 Million USD | 28.34% |
| 2023 FY | -7.59 Million USD | 62.95% |
| 2023 Q3 | -2.41 Million USD | -21.29% |
| 2022 FY | -20.5 Million USD | 65.07% |
| 2022 Q2 | -2.9 Million USD | 46.45% |
| 2022 Q1 | -5.43 Million USD | 69.87% |
| 2022 Q4 | -5.45 Million USD | 17.79% |
| 2022 Q3 | -6.63 Million USD | -128.06% |
| 2021 Q4 | -18.02 Million USD | -230.5% |
| 2021 Q1 | -29.67 Million USD | -98.73% |
| 2021 Q2 | -4.86 Million USD | 83.62% |
| 2021 Q3 | -5.45 Million USD | -12.18% |
| 2021 FY | -58.69 Million USD | -85.64% |
| 2020 Q2 | -8.77 Million USD | -413.99% |
| 2020 FY | -31.61 Million USD | 22.46% |
| 2020 Q1 | -1.7 Million USD | -16.19% |
| 2020 Q4 | -14.93 Million USD | -419.23% |
| 2020 Q3 | -2.87 Million USD | 67.24% |
| 2019 Q2 | -2.78 Million USD | 38.16% |
| 2019 FY | -40.77 Million USD | 84.27% |
| 2019 Q4 | -1.47 Million USD | 95.08% |
| 2019 Q3 | -29.87 Million USD | -971.28% |
| 2019 Q1 | -4.51 Million USD | -6.59% |
| 2018 Q2 | -9.08 Million USD | 10.01% |
| 2018 FY | -259.18 Million USD | -80.94% |
| 2018 Q4 | -4.23 Million USD | 98.21% |
| 2018 Q1 | -10.09 Million USD | -67.46% |
| 2018 Q3 | -235.78 Million USD | -2496.44% |
| 2017 Q2 | -2.83 Million USD | -22.25% |
| 2017 Q4 | -6.02 Million USD | 95.44% |
| 2017 FY | -143.24 Million USD | -781.06% |
| 2017 Q1 | -2.31 Million USD | 18.17% |
| 2017 Q3 | -132.07 Million USD | -4567.0% |
| 2016 Q4 | -2.82 Million USD | 22.07% |
| 2016 Q3 | -3.63 Million USD | -335.26% |
| 2016 Q1 | 25.94 Million USD | 169.42% |
| 2016 Q2 | 1.54 Million USD | -94.05% |
| 2016 FY | 21.03 Million USD | 164.27% |
| 2015 Q3 | -1.69 Million USD | -106.3% |
| 2015 FY | -32.72 Million USD | -39.32% |
| 2015 Q4 | -37.37 Million USD | -2109.1% |
| 2015 Q1 | -20.51 Million USD | -10.09% |
| 2015 Q2 | 26.86 Million USD | 230.92% |
| 2014 Q3 | -4.22 Million USD | -1510.69% |
| 2014 Q1 | -371 Thousand USD | -4.8% |
| 2014 Q2 | -262 Thousand USD | 29.38% |
| 2014 Q4 | -18.63 Million USD | -341.61% |
| 2014 FY | -23.48 Million USD | -4588.42% |
| 2013 Q3 | -319 Thousand USD | -4.25% |
| 2013 FY | -501 Thousand USD | 90.31% |
| 2013 Q4 | -354 Thousand USD | -10.97% |
| 2013 Q2 | -306 Thousand USD | -165.38% |
| 2013 Q1 | 468 Thousand USD | 161.5% |
| 2012 Q2 | -2.39 Million USD | -289.43% |
| 2012 Q1 | -615 Thousand USD | 45.96% |
| 2012 FY | -5.17 Million USD | -39.76% |
| 2012 Q4 | -761 Thousand USD | 45.64% |
| 2012 Q3 | -1.4 Million USD | 41.54% |
| 2011 Q2 | -662 Thousand USD | 65.57% |
| 2011 Q3 | 23 Thousand USD | 103.47% |
| 2011 FY | -3.7 Million USD | -23.54% |
| 2011 Q4 | -1.13 Million USD | -5047.83% |
| 2011 Q1 | -1.92 Million USD | -190.48% |
| 2010 Q4 | -662 Thousand USD | -4.58% |
| 2010 Q2 | 399 Thousand USD | 119.01% |
| 2010 Q3 | -633 Thousand USD | -258.65% |
| 2010 FY | -2.99 Million USD | -33.35% |
| 2010 Q1 | -2.09 Million USD | -56.99% |
| 2009 Q1 | -286 Thousand USD | 50.86% |
| 2009 FY | -2.24 Million USD | 55.13% |
| 2009 Q2 | -355 Thousand USD | -24.13% |
| 2009 Q4 | -1.33 Million USD | -398.88% |
| 2009 Q3 | -268 Thousand USD | 24.51% |
| 2008 Q3 | -797 Thousand USD | 68.54% |
| 2008 Q2 | -2.53 Million USD | -131.54% |
| 2008 FY | -5 Million USD | -1162.85% |
| 2008 Q1 | -1.09 Million USD | -490.71% |
| 2008 Q4 | -582 Thousand USD | 26.98% |
| 2007 Q1 | -774 Thousand USD | 74.35% |
| 2007 Q2 | 1.08 Million USD | 240.18% |
| 2007 Q4 | 280 Thousand USD | 333.33% |
| 2007 FY | 471 Thousand USD | 109.53% |
| 2007 Q3 | -120 Thousand USD | -111.06% |
| 2006 Q2 | -579 Thousand USD | 16.09% |
| 2006 Q4 | -3.01 Million USD | -362.17% |
| 2006 Q1 | -690 Thousand USD | 69.22% |
| 2006 Q3 | -653 Thousand USD | -12.78% |
| 2006 FY | -4.94 Million USD | -58.89% |
| 2005 FY | -3.1 Million USD | -17.06% |
| 2005 Q4 | -2.24 Million USD | -605.03% |
| 2005 Q3 | -318 Thousand USD | -6.0% |
| 2005 Q2 | -300 Thousand USD | -20.48% |
| 2005 Q1 | -249 Thousand USD | 69.52% |
| 2004 Q2 | -1.19 Million USD | -101.18% |
| 2004 FY | -2.65 Million USD | -235.78% |
| 2004 Q4 | -817 Thousand USD | -1441.51% |
| 2004 Q3 | -53 Thousand USD | 95.56% |
| 2004 Q1 | -593 Thousand USD | -169.55% |
| 2003 Q3 | -144 Thousand USD | 48.2% |
| 2003 FY | -791 Thousand USD | 3.77% |
| 2003 Q1 | -149 Thousand USD | 9.7% |
| 2003 Q2 | -278 Thousand USD | -86.58% |
| 2003 Q4 | -220 Thousand USD | -52.78% |
| 2002 FY | -822 Thousand USD | 76.48% |
| 2002 Q4 | -165 Thousand USD | 44.63% |
| 2002 Q3 | -298 Thousand USD | -85.09% |
| 2002 Q2 | -161 Thousand USD | 18.69% |
| 2002 Q1 | -198 Thousand USD | 12.39% |
| 2001 Q2 | -1.75 Million USD | -52.96% |
| 2001 FY | -3.49 Million USD | 25.38% |
| 2001 Q4 | -226 Thousand USD | 38.42% |
| 2001 Q1 | -1.14 Million USD | 23.26% |
| 2001 Q3 | -367 Thousand USD | 79.1% |
| 2000 Q2 | -1.1 Million USD | -13.74% |
| 2000 Q1 | -968 Thousand USD | -95.56% |
| 2000 FY | -4.68 Million USD | -4.2% |
| 2000 Q3 | -1.11 Million USD | -1.63% |
| 2000 Q4 | -1.49 Million USD | -33.69% |
| 1999 FY | -4.49 Million USD | 36.69% |
| 1999 Q2 | -1.8 Million USD | -50.0% |
| 1999 Q1 | -1.2 Million USD | 40.0% |
| 1999 Q3 | -1.1 Million USD | 38.89% |
| 1999 Q4 | -495 Thousand USD | 55.0% |
| 1998 Q1 | -1.8 Million USD | -63.64% |
| 1998 Q2 | -1.1 Million USD | 38.89% |
| 1998 Q3 | -2.1 Million USD | -90.91% |
| 1998 Q4 | -2 Million USD | 4.76% |
| 1998 FY | -7.1 Million USD | -36.54% |
| 1997 Q1 | -1.3 Million USD | 13.33% |
| 1997 Q3 | -1.4 Million USD | 0.0% |
| 1997 FY | -5.2 Million USD | 13.33% |
| 1997 Q4 | -1.1 Million USD | 21.43% |
| 1997 Q2 | -1.4 Million USD | -7.69% |
| 1996 Q4 | -1.5 Million USD | -7.14% |
| 1996 Q1 | -1.5 Million USD | 16.67% |
| 1996 FY | -6 Million USD | 32.58% |
| 1996 Q3 | -1.4 Million USD | 6.67% |
| 1996 Q2 | -1.5 Million USD | 0.0% |
| 1995 FY | -8.9 Million USD | -58.93% |
| 1995 Q4 | -1.8 Million USD | 62.5% |
| 1995 Q3 | -4.8 Million USD | -220.0% |
| 1995 Q2 | -1.5 Million USD | -87.5% |
| 1995 Q1 | -800 Thousand USD | 0.0% |
| 1994 Q3 | -4.4 Million USD | -2100.0% |
| 1994 Q4 | -800 Thousand USD | 81.82% |
| 1994 FY | -5.6 Million USD | -273.33% |
| 1994 Q1 | -200 Thousand USD | -100.0% |
| 1994 Q2 | -200 Thousand USD | 0.0% |
| 1993 Q2 | -900 Thousand USD | 0.0% |
| 1993 Q3 | -400 Thousand USD | 55.56% |
| 1993 Q4 | -100 Thousand USD | 75.0% |
| 1993 FY | -1.5 Million USD | -400.0% |
| 1993 Q1 | - USD | 100.0% |
| 1992 Q4 | -200 Thousand USD | 0.0% |
| 1992 Q1 | -100 Thousand USD | 0.0% |
| 1992 Q2 | -100 Thousand USD | 0.0% |
| 1992 Q3 | - USD | 100.0% |
| 1992 FY | -300 Thousand USD | -50.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q4 | -100 Thousand USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 FY | -200 Thousand USD | -122.22% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | 900 Thousand USD | 28.57% |
| 1990 Q2 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 FY | 700 Thousand USD | 600.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 47.886% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 96.627% |
| IO Biotech, Inc. | -86.08 Million USD | 91.175% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 73.299% |
| Organovo Holdings, Inc. | -14.67 Million USD | 48.218% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -89.927% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -13.985% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 93.488% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 88.448% |
| Savara Inc. | -54.69 Million USD | 86.111% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 89.941% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 96.907% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 82.968% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 92.271% |
| Soligenix, Inc. | -6.14 Million USD | -23.715% |
| Aptose Biosciences Inc. | -51.2 Million USD | 85.164% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 90.842% |
| Century Therapeutics, Inc. | -136.67 Million USD | 94.441% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 64.939% |
| Precision BioSciences, Inc. | -61.31 Million USD | 87.611% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 96.825% |
| Kura Oncology, Inc. | -152.63 Million USD | 95.023% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -83.743% |
| Dyadic International, Inc. | -6.79 Million USD | -11.795% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 91.485% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 93.275% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -1235.149% |
| Autolus Therapeutics plc | -208.38 Million USD | 96.354% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -711.645% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 89.269% |
| GRI Bio, Inc. | -13.03 Million USD | 41.727% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 93.878% |
| IGM Biosciences, Inc. | -246.41 Million USD | 96.917% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 93.129% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 81.995% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 51.902% |
| Opthea Limited | -220.24 Million USD | 96.551% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 92.491% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 97.249% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 95.291% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 114.566% |
| Surrozen, Inc. | -43.04 Million USD | 82.35% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -49.341% |
| Cingulate Inc. | -23.53 Million USD | 67.72% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 85.485% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.674% |
| Acelyrin, Inc. | -381.64 Million USD | 98.009% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 94.972% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 84.472% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 74.442% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 95.384% |
| ADMA Biologics, Inc. | -28.23 Million USD | 73.097% |
| PureTech Health plc | -65.69 Million USD | 88.436% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 80.757% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 53.916% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 89.642% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 94.831% |
| Synaptogenix, Inc. | -6.03 Million USD | -25.809% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 53.128% |
| ChromaDex Corporation | -4.93 Million USD | -53.848% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 60.076% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 9.583% |
| Exelixis, Inc. | 207.76 Million USD | 103.657% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 85.369% |
| Better Therapeutics, Inc. | -39.76 Million USD | 80.893% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 94.722% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 98.563% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 97.053% |
| Seer, Inc. | -86.27 Million USD | 91.195% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 75.294% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 81.901% |
| Gritstone bio, Inc. | -138.49 Million USD | 94.514% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 88.215% |
| Avid Bioservices, Inc. | -140.75 Million USD | 94.603% |
| Insmed Incorporated | -749.56 Million USD | 98.986% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 69.928% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 75.916% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 95.279% |
| MediWound Ltd. | -6.71 Million USD | -13.118% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 95.757% |
| Fortress Biotech, Inc. | -60.63 Million USD | 87.471% |
| OmniAb, Inc. | -50.61 Million USD | 84.992% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 93.32% |
| Zai Lab Limited | -334.62 Million USD | 97.73% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 97.655% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 94.41% |
| Veracyte, Inc. | -74.4 Million USD | 89.79% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 85.98% |
| FibroGen, Inc. | -284.23 Million USD | 97.327% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 90.954% |
| ContextLogic Inc. | -317 Million USD | 97.603% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 27.909% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -8.499% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 90.688% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 101.831% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -13.642% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 66.318% |
| ImmuCell Corporation | -5.77 Million USD | -31.559% |
| Fortrea Holdings Inc. | -3.4 Million USD | -123.441% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 94.001% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 88.215% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 92.282% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 98.748% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 86.236% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 88.87% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -13243.521% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 96.646% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 65.883% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -43.704% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 45.913% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 71.798% |
| Senti Biosciences, Inc. | -92.91 Million USD | 91.824% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 27.076% |
| Apollomics, Inc. | -172.6 Million USD | 95.599% |
| 89bio, Inc. | -142.18 Million USD | 94.657% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 96.299% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 59.037% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 93.496% |
| Ardelyx, Inc. | -66.06 Million USD | 88.501% |
| Pluri Inc. | -20.88 Million USD | 63.63% |
| Prothena Corporation plc | -147.02 Million USD | 94.833% |
| Pulmatrix, Inc. | -14.12 Million USD | 46.201% |
| Celularity Inc. | -196.29 Million USD | 96.13% |
| MeiraGTx Holdings plc | -84.02 Million USD | 90.959% |
| Omeros Corporation | -117.81 Million USD | 93.552% |
| Ainos, Inc. | -13.77 Million USD | 44.832% |
| Humacyte, Inc. | -110.77 Million USD | 93.142% |
| Mesoblast Limited | -87.95 Million USD | 91.363% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 57.757% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 66.87% |
| Blueprint Medicines Corporation | -506.98 Million USD | 98.502% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 88.774% |
| Summit Therapeutics Inc. | -614.92 Million USD | 98.765% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 78.381% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 95.418% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 98.421% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 92.756% |
| Cytokinetics, Incorporated | -526.24 Million USD | 98.556% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 78.935% |
| Nutriband Inc. | -5.48 Million USD | -38.497% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 81.205% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.175% |
| Evogene Ltd. | -23.87 Million USD | 68.185% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 93.657% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 3.166% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 98.819% |
| BioLineRx Ltd. | -60.61 Million USD | 87.467% |
| Atai Life Sciences N.V. | -40.22 Million USD | 81.113% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 74.126% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 90.263% |
| MediciNova, Inc. | -8.57 Million USD | 11.369% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 93.837% |
| MiMedx Group, Inc. | 67.43 Million USD | 111.265% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 98.788% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 95.04% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 96.371% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 52.405% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 74.803% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 92.466% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 96.78% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 153.941% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 96.063% |
| Allakos Inc. | -185.7 Million USD | 95.909% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 92.195% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 107.158% |
| BioAtla, Inc. | -123.46 Million USD | 93.847% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 97.679% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 79.439% |
| Precigen, Inc. | -95.9 Million USD | 92.079% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -58.553% |
| XOMA Corporation | -40.83 Million USD | 81.394% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 92.542% |
| Incyte Corporation | 597.59 Million USD | 101.271% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 93.59% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 91.335% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 68.787% |
| CRISPR Therapeutics AG | -153.61 Million USD | 95.054% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 94.994% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 78.368% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 6.116% |
| UroGen Pharma Ltd. | -102.24 Million USD | 92.57% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 92.886% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 2.317% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 63.546% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 92.744% |
| Chimerix, Inc. | -82.09 Million USD | 90.746% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 87.12% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -101.742% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 94.323% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 46.825% |
| Portage Biotech Inc. | -75.33 Million USD | 89.916% |
| OncoCyte Corporation | -27.78 Million USD | 72.654% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 43.379% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 9.095% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 31.691% |
| Purple Biotech Ltd. | -19.88 Million USD | 61.786% |
| NextCure, Inc. | -62.72 Million USD | 87.888% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 56.604% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 2.536% |
| Generation Bio Co. | -126.61 Million USD | 94.0% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 96.78% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 87.797% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -111.734% |
| NLS Pharmaceutics AG | -12.17 Million USD | 37.586% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 89.434% |
| Novavax, Inc. | -545.06 Million USD | 98.606% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -43.447% |
| Curis, Inc. | -47.41 Million USD | 83.977% |
| Daré Bioscience, Inc. | -30.16 Million USD | 74.812% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -36.416% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 49.985% |
| Bicycle Therapeutics plc | -180.66 Million USD | 95.795% |
| BeiGene, Ltd. | -881.7 Million USD | 99.138% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 64.323% |
| Alector, Inc. | -130.39 Million USD | 94.174% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 90.378% |
| Erasca, Inc. | -125.04 Million USD | 93.924% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 85.347% |
| Aura Biosciences, Inc. | -76.4 Million USD | 90.057% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 85.121% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 68.635% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -51.925% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 69.046% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 104.532% |
| Histogen Inc. | -10.62 Million USD | 28.472% |
| Fortress Biotech, Inc. | -60.63 Million USD | 87.471% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 96.42% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 96.762% |
| Galecto, Inc. | -38.34 Million USD | 80.19% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 1.023% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 96.231% |
| Molecular Templates, Inc. | -8.12 Million USD | 6.487% |
| PDS Biotechnology Corporation | -42.94 Million USD | 82.309% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 115.419% |
| Amarin Corporation plc | -59.11 Million USD | 87.148% |
| TG Therapeutics, Inc. | 12.67 Million USD | 159.951% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 56.367% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 94.628% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 96.052% |
| Onconetix, Inc. | -37.4 Million USD | 79.692% |
| MacroGenics, Inc. | -9.05 Million USD | 16.129% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 64.545% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 23.923% |
| Adagene Inc. | -18.94 Million USD | 59.903% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 96.852% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 96.542% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 105.741% |
| SciSparc Ltd. | -5.12 Million USD | -48.321% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -6217.461% |
| Minerva Neurosciences, Inc. | -30 Million USD | 74.681% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 89.578% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 90.785% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 97.102% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 97.778% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 98.274% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 85.15% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 23.061% |
| 2seventy bio, Inc. | -217.57 Million USD | 96.508% |
| Clene Inc. | -49.5 Million USD | 84.654% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 84.632% |
| GeoVax Labs, Inc. | -25.96 Million USD | 70.743% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 59.661% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 89.572% |
| Scopus BioPharma Inc. | -11.6 Million USD | 34.564% |
| Absci Corporation | -110.56 Million USD | 93.129% |
| XBiotech Inc. | -24.55 Million USD | 69.064% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 95.276% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 87.88% |
| Entera Bio Ltd. | -8.88 Million USD | 14.535% |
| Trevena, Inc. | -40.28 Million USD | 81.144% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 93.328% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 92.557% |
| INmune Bio, Inc. | -30 Million USD | 74.683% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 76.655% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 89.011% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -9.91% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 80.941% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 1.474% |
| Jaguar Health, Inc. | -41.3 Million USD | 81.605% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 76.614% |
| NexImmune, Inc. | -32.34 Million USD | 76.512% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 87.233% |
| Clearmind Medicine Inc. | -11.95 Million USD | 36.454% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 64.277% |
| Kronos Bio, Inc. | -112.67 Million USD | 93.257% |
| Innoviva, Inc. | 179.72 Million USD | 104.227% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 96.807% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.192% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 89.021% |
| Verastem, Inc. | -87.36 Million USD | 91.304% |
| ProKidney Corp. | -35.46 Million USD | 78.581% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -299439.08% |
| Imunon, Inc. | -19.51 Million USD | 61.071% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 91.155% |
| Statera Biopharma, Inc. | -174.4 Million USD | 95.644% |
| ImmunityBio, Inc. | -583.19 Million USD | 98.697% |
| Korro Bio, Inc. | -81.17 Million USD | 90.641% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 93.18% |
| Kineta, Inc. | -14.09 Million USD | 46.117% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 110.639% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 65.914% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 95.034% |
| Celularity Inc. | -196.29 Million USD | 96.13% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 96.459% |
| CalciMedica, Inc. | -34.35 Million USD | 77.888% |
| Cibus, Inc. | -267.62 Million USD | 97.161% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 94.266% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 94.627% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 81.161% |
| Kodiak Sciences Inc. | -260.49 Million USD | 97.084% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 97.318% |
| Annexon, Inc. | -134.23 Million USD | 94.341% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 93.516% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 87.592% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 78.415% |
| Moderna, Inc. | -4.71 Billion USD | 99.839% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 90.807% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 97.926% |
| Vor Biopharma Inc. | -117.86 Million USD | 93.554% |
| Eyenovia, Inc. | -27.26 Million USD | 72.132% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 60.802% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 135.186% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 94.387% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 86.791% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1320.0% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 87.604% |
| Immunocore Holdings plc | -55.28 Million USD | 86.259% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 92.533% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 81.501% |
| Alkermes plc | 355.75 Million USD | 102.135% |
| Arcellx, Inc. | -70.69 Million USD | 89.253% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 90.58% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 97.4% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 72.747% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 74.708% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 9.309% |
| Moolec Science SA | -51.78 Million USD | 85.331% |
| Biomea Fusion, Inc. | -117.25 Million USD | 93.521% |
| RenovoRx, Inc. | -10.23 Million USD | 25.753% |
| Geron Corporation | -184.12 Million USD | 95.874% |
| Mereo BioPharma Group plc | -29.46 Million USD | 74.218% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 88.66% |
| Royalty Pharma plc | 1.13 Billion USD | 100.669% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 94.412% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 14.562% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 59.732% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 64.238% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 95.575% |
| Humacyte, Inc. | -110.77 Million USD | 93.142% |
| Structure Therapeutics Inc. | -89.62 Million USD | 91.523% |
| NLS Pharmaceutics AG | -12.17 Million USD | 37.586% |
| Genelux Corporation | -28.29 Million USD | 73.153% |
| ESSA Pharma Inc. | -26.58 Million USD | 71.421% |
| aTyr Pharma, Inc. | -50.38 Million USD | 84.923% |
| Notable Labs, Ltd. | -11.26 Million USD | 32.555% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 23.631% |
| Mustang Bio, Inc. | -51.6 Million USD | 85.278% |
| Immunovant, Inc. | -259.33 Million USD | 97.071% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -11184.07% |
| Vericel Corporation | -3.18 Million USD | -138.749% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 102.698% |
| Akari Therapeutics, Plc | -10 Million USD | 24.091% |
| Acasti Pharma Inc. | -12.85 Million USD | 40.893% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 66.172% |
| Vaxcyte, Inc. | -402.26 Million USD | 98.111% |
| Orgenesis Inc. | -55.36 Million USD | 86.277% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 84.146% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 39.078% |
| GH Research PLC | -35.58 Million USD | 78.652% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 74.24% |
| PepGen Inc. | -78.62 Million USD | 90.338% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 74.48% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 92.31% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -58.553% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -49.341% |
| Silo Pharma, Inc. | -3.7 Million USD | -105.286% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 41.883% |
| Belite Bio, Inc | -31.63 Million USD | 75.983% |
| Pharming Group N.V. | -10.54 Million USD | 27.977% |
| XOMA Corporation | -40.83 Million USD | 81.394% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 90.183% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 68.787% |
| Bionomics Limited | -15.49 Billion USD | 99.951% |
| Xencor, Inc. | -126.08 Million USD | 93.975% |
| Replimune Group, Inc. | -215.79 Million USD | 96.48% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 89.705% |
| Cassava Sciences, Inc. | -97.21 Million USD | 92.186% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 402.79% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -3.902% |
| Turnstone Biologics Corp. | -55.2 Million USD | 86.237% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 62.56% |
| GeoVax Labs, Inc. | -25.96 Million USD | 70.743% |
| MEI Pharma, Inc. | 17.77 Million USD | 142.733% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 92.14% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 9.309% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 52.749% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 73.865% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -8.235% |
| scPharmaceuticals Inc. | -54.81 Million USD | 86.139% |
| HilleVax, Inc. | -123.56 Million USD | 93.852% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 92.086% |
| Tharimmune, Inc. | -9.31 Million USD | 18.479% |
| Genprex, Inc. | -30.86 Million USD | 75.383% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 71.039% |
| Immunic, Inc. | -93.61 Million USD | 91.885% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 74.756% |
| Aptorum Group Limited | -2.82 Million USD | -168.954% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 80.515% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 71.039% |
| OKYO Pharma Limited | -16.82 Thousand USD | -45051.812% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 50.813% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 74.52% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 1443.484% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 94.988% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -60469.144% |
| bluebird bio, Inc. | -211.91 Million USD | 96.415% |
| DBV Technologies S.A. | -72.72 Million USD | 89.554% |
| Compugen Ltd. | -18.75 Million USD | 59.491% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -51.925% |
| Peak Bio, Inc. | -1259.26 USD | -603190.822% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 81.082% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -33.421% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 77.722% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 84.534% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 83.502% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 87.42% |
| Benitec Biopharma Inc. | -21.75 Million USD | 65.073% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 97.758% |
| Adicet Bio, Inc. | -142.65 Million USD | 94.675% |
| Prime Medicine, Inc. | -198.13 Million USD | 96.166% |
| Aditxt, Inc. | -32.38 Million USD | 76.539% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 97.967% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -3.902% |
| Quantum-Si incorporated | -95.96 Million USD | 92.083% |
| GlycoMimetics, Inc. | -36.89 Million USD | 79.412% |
| PolyPid Ltd. | -23.86 Million USD | 68.167% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 51.71% |
| Invivyd, Inc. | -198.64 Million USD | 96.176% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 12.543% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 69.722% |
| CorMedix Inc. | -46.33 Million USD | 83.606% |
| Instil Bio, Inc. | -156.08 Million USD | 95.133% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 97.684% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 133.438% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 89.837% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 133.311% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 73.945% |
| AbCellera Biologics Inc. | -146.39 Million USD | 94.811% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 90.59% |
| Surrozen, Inc. | -43.04 Million USD | 82.35% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 86.968% |
| Verona Pharma plc | -54.36 Million USD | 86.027% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 91.579% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 98.765% |
| Evaxion Biotech A/S | -22.12 Million USD | 65.663% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 96.203% |
| Shattuck Labs, Inc. | -87.29 Million USD | 91.298% |
| AlloVir, Inc. | -190.41 Million USD | 96.01% |
| BioVie Inc. | -32.12 Million USD | 76.348% |
| Codexis, Inc. | -76.24 Million USD | 90.035% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 79.655% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -13.985% |
| Agenus Inc. | -245.76 Million USD | 96.909% |
| Virax Biolabs Group Limited | -6.73 Million USD | -12.823% |
| Lantern Pharma Inc. | -15.96 Million USD | 52.404% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 96.804% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 78.786% |
| Immix Biopharma, Inc. | -15.42 Million USD | 50.752% |
| Celcuity Inc. | -63.77 Million USD | 88.089% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 81.668% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 85.494% |
| IN8bio, Inc. | -30 Million USD | 74.683% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 26.79% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 73.862% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 95.711% |
| Liquidia Corporation | -78.5 Million USD | 90.323% |
| Quantum-Si incorporated | -95.96 Million USD | 92.083% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 52.405% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 95.835% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 72.109% |
| United Therapeutics Corporation | 984.8 Million USD | 100.771% |
| Solid Biosciences Inc. | -96.01 Million USD | 92.088% |
| Immuneering Corporation | -53.47 Million USD | 85.792% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 73.945% |
| uniQure N.V. | -308.47 Million USD | 97.537% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 90.057% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -43834.297% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 93.845% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 86.041% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 88.983% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -76.612% |
| Cue Biopharma, Inc. | -50.73 Million USD | 85.026% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 65.872% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 86.026% |
| Zura Bio Limited | -60.36 Million USD | 87.414% |
| Forte Biosciences, Inc. | -31.47 Million USD | 75.864% |
| Elevation Oncology, Inc. | -45.7 Million USD | 83.378% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1320.0% |
| Immunome, Inc. | -106.8 Million USD | 92.887% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 82.122% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 92.397% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 94.377% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 93.905% |
| Altimmune, Inc. | -88.44 Million USD | 91.411% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 87.272% |
| Rallybio Corporation | -74.56 Million USD | 89.811% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 42.948% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 82.558% |
| Moolec Science SA | -51.78 Million USD | 85.331% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 7.373% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -326.319% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 81.965% |
| NeurAxis, Inc. | -14.62 Million USD | 48.061% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 93.618% |
| Lumos Pharma, Inc. | -34.03 Million USD | 77.678% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 92.397% |
| 180 Life Sciences Corp. | -19.93 Million USD | 61.891% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 90.842% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 352.494% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -299439.08% |
| Nutriband Inc. | -5.48 Million USD | -38.497% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 84.371% |
| argenx SE | -295.05 Million USD | 97.425% |
| Neurogene Inc. | -36.31 Million USD | 79.081% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 95.351% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 10.634% |
| CervoMed Inc. | -2.17 Million USD | -249.79% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 92.26% |
| Sesen Bio, Inc. | -19.88 Million USD | 61.793% |
| AnaptysBio, Inc. | -163.61 Million USD | 95.357% |
| Design Therapeutics, Inc. | -66.86 Million USD | 88.638% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 90.669% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 79.946% |
| Achilles Therapeutics plc | -69.66 Million USD | 89.095% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 24.834% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 92.456% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 90.145% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 77.636% |
| MoonLake Immunotherapeutics | -36 Million USD | 78.901% |
| Palisade Bio, Inc. | -12.3 Million USD | 38.236% |
| Beam Therapeutics Inc. | -132.52 Million USD | 94.268% |
| AEON Biopharma, Inc. | -52.55 Million USD | 85.545% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 89.387% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 39.291% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 98.289% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 93.191% |
| Athira Pharma, Inc. | -117.67 Million USD | 93.544% |
| Vaccinex, Inc. | -20.25 Million USD | 62.486% |
| HCW Biologics Inc. | -24.99 Million USD | 69.605% |
| XOMA Corporation | -40.83 Million USD | 81.394% |
| Nektar Therapeutics | -276.05 Million USD | 97.248% |
| Arvinas, Inc. | -367.3 Million USD | 97.932% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -11184.07% |
| Merus N.V. | -154.93 Million USD | 95.097% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 92.202% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 75.794% |
| Rezolute, Inc. | -68.45 Million USD | 88.903% |
| Clene Inc. | -49.5 Million USD | 84.654% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 50.744% |
| BeyondSpring Inc. | -21.02 Million USD | 63.869% |
| Synlogic, Inc. | -57.28 Million USD | 86.738% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 36.165% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 29.826% |
| Peak Bio, Inc. | -1259.26 USD | -603190.822% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 79.67% |
| Krystal Biotech, Inc. | 10.93 Million USD | 169.493% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 94.691% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 97.663% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -64.474% |
| MannKind Corporation | -11.93 Million USD | 36.363% |
| Ikena Oncology, Inc. | -68.16 Million USD | 88.855% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 63.85% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 91.825% |
| Gossamer Bio, Inc. | -179.81 Million USD | 95.775% |
| CohBar, Inc. | -11.96 Million USD | 36.491% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 70.541% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 74.803% |
| Legend Biotech Corporation | -518.25 Million USD | 98.534% |
| Mural Oncology plc | -207.44 Million USD | 96.338% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 93.879% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 58.463% |
| Disc Medicine, Inc. | -76.42 Million USD | 90.06% |
| Champions Oncology, Inc. | -7.27 Million USD | -4.412% |
| REGENXBIO Inc. | -263.49 Million USD | 97.117% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 28.418% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 84.008% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 79.999% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 92.415% |
| Vaxart, Inc. | -82.46 Million USD | 90.788% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 2376.166% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 79.764% |
| Cellectis S.A. | -101.05 Million USD | 92.483% |
| Longeveron Inc. | -21.41 Million USD | 64.522% |
| Repare Therapeutics Inc. | -93.79 Million USD | 91.901% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.583% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 89.325% |
| Revolution Medicines, Inc. | -436.36 Million USD | 98.259% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -15.614% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 75.354% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 89.043% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 88.264% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 22.567% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.21% |
| Denali Therapeutics Inc. | -145.22 Million USD | 94.769% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -6217.461% |
| Veru Inc. | -93.15 Million USD | 91.845% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 71.893% |
| Cingulate Inc. | -23.53 Million USD | 67.72% |
| Passage Bio, Inc. | -102.06 Million USD | 92.556% |
| Context Therapeutics Inc. | -23.96 Million USD | 68.299% |
| Exicure, Inc. | -16.91 Million USD | 55.085% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 95.979% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 79.883% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 98.259% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -16.745% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 95.886% |
| Nuvalent, Inc. | -126.21 Million USD | 93.981% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 27.755% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 91.256% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 75.128% |
| OmniAb, Inc. | -50.61 Million USD | 84.992% |
| Anew Medical, Inc. | 1.34 Million USD | 664.361% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 52.652% |
| Lipocine Inc. | -16.35 Million USD | 53.541% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 88.558% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 88.069% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 81.995% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 84.162% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 61.691% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 98.597% |
| Ocugen, Inc. | -63.07 Million USD | 87.956% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 92.064% |
| Q32 Bio Inc. | -112.96 Million USD | 93.275% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 55.811% |
| Alumis Inc. Common Stock | -154.99 Million USD | 95.098% |
| Equillium, Inc. | -13.33 Million USD | 43.03% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 87.415% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 4.893% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 59.7% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 87.142% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 93.367% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 58.662% |
| Dominari Holdings Inc. | -22.88 Million USD | 66.799% |
| Edesa Biotech, Inc. | -8.37 Million USD | 9.283% |
| vTv Therapeutics Inc. | -20.25 Million USD | 62.484% |
| Bio-Techne Corporation | 168.1 Million USD | 104.519% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 97.842% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 105.896% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 93.764% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 79.976% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 93.256% |
| Nkarta, Inc. | -117.5 Million USD | 93.535% |
| BioCardia, Inc. | -11.57 Million USD | 34.344% |
| Iterum Therapeutics plc | -38.37 Million USD | 80.201% |